<DOC>
	<DOCNO>NCT00622284</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability BI 1356 ( 5.0 mg daily ) compare glimepiride give 104 week add-on therapy preferably &gt; 1500 mg metformin patient type 2 diabetes mellitus insufficient glycaemic control</brief_summary>
	<brief_title>Efficacy Safety BI 1356 Combination With Metformin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient diagnosis type 2 diabetes mellitus previously treat metformin alone metformin one oral antidiabetic drug 2 . Glycosylated haemoglobin ( HbA1c ) 6.0 9.0 % screen patient treat metformin one oral antidiabetic drug 3 . HbA1c 6.5 10.0 % screen patient treated metformin alone 4 . HbA1c 6.5 10.0 % begin placebo runin phase Exclusion criterion : 1 . Myocardial infarction , stroke transient ischemic attack ( TIA ) 2 . Impaired hepatic function 3 . Renal failure renal impairment 4 . Treatment rosiglitazone pioglitazone within 6 month prior screen 5 . Treatment insulin glucagonlike peptide 1 ( GLP1 ) analogue/antagonists within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>